PuraPharm Corporation Limited reported unaudited consolidated financial results for the six months ended June 30, 2018. For the six months, profit before tax was HKD 15,692,000 against HKD 13,787,000 for the same period of last year. Profit attributable to owners of the parent was HKD 13,348,000 or 5.4 HK cents per diluted share against HKD 9,138,000 or 4.0 HK cents per diluted share for the same period of last year. Revenue was HKD 386,604,000 against HKD 263,093,000 for the same period of last year. Net cash flows generated from operating activities was HKD 44,938,000 against outflow of HKD 81,476,000 for the same period of last year. Purchases of property, plant and equipment was HKD 30,522,000 against outflow of HKD 35,436,000 for the same period of last year. Addition to other intangible assets was HKD 3,248,000 against outflow of HKD 5,065,000 for the same period of last year.